enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Esomeprazole - Wikipedia

   en.wikipedia.org/wiki/Esomeprazole

   Esomeprazole strontium delayed-release capsules, 49.3 mg 40 mg Nexium (esomeprazole magnesium) capsules. Esomeprazole is available as delayed-release capsules in the United States or as delayed-release tablets in Australia, the United Kingdom, and Canada (containing esomeprazole magnesium) in strengths of 20 and 40 mg, as delayed-release ...

3. Modified-release dosage - Wikipedia

   en.wikipedia.org/wiki/Modified-release_dosage

   Modified-release dosage is a mechanism that (in contrast to immediate-release dosage) delivers a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific target in the body (targeted-release dosage). [1]

4. Duloxetine - Wikipedia

   en.wikipedia.org/wiki/Duloxetine

   Duloxetine, administered in a single oral dose of 20 mg or 40 mg has plasma elimination half-life of 10–12 h [9] [4] and its pharmacokinetics are dose proportional over the therapeutic range. [4] Steady-state concentration is usually achieved after 3 days.

5. Nexium - Wikipedia

   en.wikipedia.org/?title=Nexium&redirect=no

   From or to a drug trade name: This is a redirect from (or to) the trade name of a drug to (or from) the international nonproprietary name (INN). When appropriate, protection levels are automatically sensed, described and categorized.

6. Naproxen/esomeprazole - Wikipedia

   en.wikipedia.org/wiki/Naproxen/esomeprazole

   Naproxen/esomeprazole, sold under the brand name Vimovo, is a pain reliever medication in the form of a tablet for oral consumption, containing naproxen, a nonsteroidal anti-inflammatory drug (NSAID), and a delayed release formulation of esomeprazole, a stomach acid–reducing proton-pump inhibitor (PPI). [2] [3] It is produced by AstraZeneca. [4]

7. Xanomeline/trospium chloride - Wikipedia

   en.wikipedia.org/wiki/Xanomeline/trospium_chloride

   Xanomeline was licensed to Karuna Therapeutics in 2012 and KarXT was subsequently created as a dual drug formulation by adding trospium. Trospium is a non-brain-penetrant and non-selective muscarinic receptor blocker that may ameliorate the peripheral side effects of xanomeline.